Exane Derivatives Sage Therapeutics, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Exane Derivatives holds 14 shares of SAGE stock, worth $121. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14
Previous 14
-0.0%
Holding current value
$121
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SAGE
# of Institutions
220Shares Held
49.8MCall Options Held
175KPut Options Held
380K-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$38.9 Million4.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$28.3 Million0.0% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$23.7 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$18.1 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...